MoonLake Immunotherapeutics (MLTX) News Today $40.28 +1.08 (+2.76%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MLTX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Ameriprise Financial Inc. Increases Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)Ameriprise Financial Inc. lifted its holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 28.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 204,373 shares of the company's stock after purchasing an additional 45,113 shares during the periodMay 21 at 3:27 AM | marketbeat.comWolfe Research Upgrades MoonLake Immunotherapeutics (MLTX)May 20 at 10:38 PM | msn.comWolfe Research Upgrades MoonLake Immunotherapeutics (NASDAQ:MLTX) to "Outperform"May 20 at 1:45 AM | americanbankingnews.comWolfe Research Upgrades MoonLake Immunotherapeutics (MLTX) with a Bullish Outlook | MLTX Stock NewsMay 19 at 2:31 PM | gurufocus.comEnsign Peak Advisors Inc Sells 33,174 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)Ensign Peak Advisors Inc reduced its stake in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 78.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,139 shares ofMay 19 at 4:14 AM | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of "Moderate Buy" from AnalystsMoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and seven have assigned aMay 19 at 2:11 AM | marketbeat.comWedbush Issues Optimistic Outlook for MLTX EarningsMay 18 at 1:35 AM | americanbankingnews.comPolar Capital Holdings Plc Raises Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX)Polar Capital Holdings Plc raised its stake in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 120.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,100,000 shares of the company's stock after purchasingMay 17, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Rating of "Moderate Buy" by AnalystsMay 17, 2025 | americanbankingnews.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Sold by MPM Bioimpact LLCMPM Bioimpact LLC lessened its holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 9.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 315,230 shares of the company's stock after sellinMay 16, 2025 | marketbeat.comParadigm Biocapital Advisors LP Purchases 840,731 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)Paradigm Biocapital Advisors LP grew its holdings in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 90.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,772,211 shares of the company'sMay 16, 2025 | marketbeat.comParkman Healthcare Partners LLC Has $2.94 Million Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)Parkman Healthcare Partners LLC reduced its holdings in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 47.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 54,294 shares of the company's stock afteMay 16, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Holdings Lowered by Schonfeld Strategic Advisors LLCSchonfeld Strategic Advisors LLC cut its position in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 95.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,911 shares of the company's stock after seMay 16, 2025 | marketbeat.comDimensional Fund Advisors LP Purchases Shares of 64,384 MoonLake Immunotherapeutics (NASDAQ:MLTX)Dimensional Fund Advisors LP purchased a new stake in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 64,384 shares of the company's stock, valued at approximately $3May 16, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Buy Rating from Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and issued a $66.00 price target on shares of MoonLake Immunotherapeutics in a report on Tuesday.May 15, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Releases Earnings Results, Beats Expectations By $0.13 EPSMoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.13.May 14, 2025 | marketbeat.comIntegral Health Asset Management LLC Sells 20,000 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)Integral Health Asset Management LLC cut its stake in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 9.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 200,000 shares of the company's stock aftMay 14, 2025 | marketbeat.comMoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business UpdateMay 13, 2025 | finanznachrichten.deDecoding MoonLake Immunotherapeutics (MLTX): A Strategic SWOT InsightMay 13, 2025 | gurufocus.comMoonLake Immunotherapeutics: Promising Clinical Developments and Market Opportunities Justify Buy RatingMay 12, 2025 | tipranks.comMoonLake Immunotherapeutics (MLTX) Strengthens Financial Position with New Funding | MLTX Stock NewsMay 12, 2025 | gurufocus.comMoonLake Immunotherapeutics Q1 2025 Earnings: EPS of -$0. ...May 12, 2025 | gurufocus.comMoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a ...May 12, 2025 | gurufocus.comMoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business UpdateMay 12, 2025 | globenewswire.comGranahan Investment Management LLC Sells 36,196 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)Granahan Investment Management LLC lowered its position in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 21.0% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 136,438 shares of the company's stock after selling 36,196 shares during thMay 12, 2025 | marketbeat.comBalyasny Asset Management L.P. Reduces Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX)Balyasny Asset Management L.P. lessened its stake in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 42.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 206,568 shares of the company's stock aftMay 11, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Acquired by Fred Alger Management LLCFred Alger Management LLC increased its holdings in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 1.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 673,773 shares of the company's stock afMay 10, 2025 | marketbeat.comCaption Management LLC Invests $670,000 in MoonLake Immunotherapeutics (NASDAQ:MLTX)Caption Management LLC bought a new stake in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 12,371 shares of the company's stock, valuMay 9, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Buys 24,576 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)The Manufacturers Life Insurance Company increased its stake in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 20.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 142,702 shares of the company's stock after buying an additionaMay 9, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Position Cut by BVF Inc. ILBVF Inc. IL cut its stake in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 9.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 19,751,284 shares of the company's stock after selling 2,000,0May 6, 2025 | marketbeat.comNeedham & Company LLC Reiterates Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)Needham & Company LLC reiterated a "buy" rating and issued a $66.00 price target on shares of MoonLake Immunotherapeutics in a research report on Wednesday.May 2, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Sees Strong Trading Volume - Should You Buy?MoonLake Immunotherapeutics (NASDAQ:MLTX) Sees Unusually-High Trading Volume - Should You Buy?May 1, 2025 | marketbeat.comMoonLake Immunotherapeutics (MLTX) Projected to Post Quarterly Earnings on TuesdayMoonLake Immunotherapeutics (NASDAQ:MLTX) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-moonlake-immunotherapeutics-stock/)May 1, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Sold by Adage Capital Partners GP L.L.C.Adage Capital Partners GP L.L.C. lowered its position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 69.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 155,000 shares of the company's stock after selMay 1, 2025 | marketbeat.comBTIG Boosts Price Target for MoonLake Immunotherapeutics (MLTX) to $85 | MLTX Stock NewsApril 30, 2025 | gurufocus.comMoonLake Immunotherapeutics: Promising Developments and Financial Strength Justify Buy RatingApril 29, 2025 | tipranks.comMoonLake Immunotherapeutics: Promising Clinical Trials and Market Potential Drive Buy RatingApril 29, 2025 | tipranks.comMoonLake Immunotherapeutics: Promising Developments and Strategic Positioning Justify Buy RatingApril 29, 2025 | tipranks.comVoya Investment Management LLC Purchases 39,657 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)Voya Investment Management LLC lifted its stake in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 9.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 448,860 shares of the company's stock after purchasing anApril 29, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stake Increased by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD increased its holdings in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 12.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,343,643 shareApril 29, 2025 | marketbeat.comMoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29April 26, 2025 | finanznachrichten.deMoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 | MLTX Stock NewsApril 25, 2025 | gurufocus.comMoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29April 25, 2025 | gurufocus.comMoonLake Immunotherapeutics Announces Capital Markets Day to Highlight Financial and Clinical ...April 25, 2025 | gurufocus.comMoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29April 25, 2025 | globenewswire.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Down 3.1% - Here's WhyMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Down 3.1% - Time to Sell?April 24, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Up 4.1% - Should You Buy?MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Up 4.1% - What's Next?April 23, 2025 | marketbeat.comIs MoonLake Immunotherapeutics (MLTX) Among the Best Guru Stocks to Buy According to Wall Street Analysts?April 23, 2025 | msn.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Average Rating of "Buy" from BrokeragesShares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) have been assigned a consensus recommendation of "Buy" from the eight brokerages that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, six have assigned aApril 23, 2025 | marketbeat.comMarshall Wace LLP Buys 90,914 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)Marshall Wace LLP increased its position in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 7.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,245,299 shares of the company's stock after acquiring an additionaApril 19, 2025 | marketbeat.com Get MoonLake Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address MLTX Media Mentions By Week MLTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MLTX News Sentiment▼1.060.65▲Average Medical News Sentiment MLTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MLTX Articles This Week▼274▲MLTX Articles Average Week Get MoonLake Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MRNA News Today QGEN News Today ASND News Today ROIV News Today RVMD News Today BBIO News Today BPMC News Today ELAN News Today LEGN News Today TGTX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MLTX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share MoonLake Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
